Roche 454 Life Sciences and SoftGenetics Sign Co-Promotion Agreement for Next-Gen Sequencing Software Tools
BRANFORD, Connecticut and STATE COLLEGE, Pennsylvania, May 9, 2012 /PRNewswire/ –
454 Life Sciences, a Roche Company, and SoftGenetics announced today that the two
firms have entered into a co-promotion agreement designed to provide users of 454
Sequencing Systems the broad range of next-generation sequencing data analysis options
provided by SoftGenetics NextGENe(R) software.
NextGENe(R) software is a free standing biologist-friendly software multi-package that
is fully compatibility with 454 Sequencing data for a wide variety of applications,
including targeted amplicon resequencing, exome sequencing, transcriptome sequencing,
forensic profiling and more. The software package provides additional options for users of
454 Sequencing Systems, in addition to the extensive GS Data Analysis Software suite
provided with the platforms.
“This agreement permits both 454 and SoftGenetics the opportunity to more fully
understand and address the rapidly changing needs of the NGS marketplace,” states
SoftGenetics co-founder John Fosnacht. “SoftGenetics welcomes the opportunity to work
closely with our colleagues at 454 Life Sciences to provide our mutual customers with
integrated sequencing and analysis systems that not only delivers the required quality and
sensitivity, but also the efficiency needed in today’s scientific and economic
SoftGenetics offers 30-day trials and no cost web-based training on its genetic
analysis software packages. Interested parties may request the software on the company
website at http://www.softgenetics.com or via email at email@example.com.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare
with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest
biotech company with truly differentiated medicines in oncology, virology, inflammation,
metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based
cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare
strategy aims at providing medicines and diagnostic tools that enable tangible
improvements in the health, quality of life and survival of patients. In 2011, Roche had
over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group
posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned
member of the Roche Group. Roche has a majority stake in
Chugai Pharmaceutical, Japan. For more information: http://www.roche.com
SoftGenetics, LLC specializes in the development of genetic analysis tools for both
research and diagnostic applications. Hallmarks of SoftGenetics software tools are
advanced technologies, providing exceptional accuracy, and sensitivity in an easy to use
Windows(R) user interface.
For life science research only. Not for use in diagnostic procedures.
454, 454 LIFE SCIENCES, and 454 SEQUENCING, and are trademarks of Roche.
The name “SoftGenetics,” the SoftGenetics logo, NextGENe, and the NextGENe
Condensation Tool are trademarks or registered trademarks of SoftGenetics, LLC.
All other product names and trademarks are the property of their respective owners.
For further information please contact: Roche Diagnostics Dr. Burkhard Ziebolz Phone: +49-8856-604830 Email: firstname.lastname@example.org 454 Life Sciences Corporation, a Roche Company Katie Montgomery Phone: +1-203-871-2300 Email: email@example.com SoftGenetics John Fosnacht Phone: +1-814-237-9340 Email: firstname.lastname@example.org
SOURCE Roche Diagnostics GmbH